A phase IIa study of HA-irinotecan, formulation of hyaluronic acid and irinotecan targeting CD44 in extensive-stage small cell lung cancer.

导出原文传递

翻译打印收藏纠错

第一作者： Muhammad,Alamgeer

第一单位： Department of Medical Oncology, Monash Medical Centre, 246 Clayton Road, Clayton, VIC, 3168, Australia. alamgeer.muhammad@hudson.org.au.

作者： Muhammad,Alamgeer ^[1] ; D,Neil Watkins ^[2] ; Ilia,Banakh ^[3] ; Beena,Kumar ^[4] ; Daniel J,Gough ^[5] ; Ben,Markman ^[6] ; Vinod,Ganju ^[7]

作者单位： Department of Medical Oncology, Monash Medical Centre, 246 Clayton Road, Clayton, VIC, 3168, Australia. alamgeer.muhammad@hudson.org.au. ^[1] Centre for Cancer Research, Hudson Institute of Medical Research, 27-31 Wright Street, Clayton, VIC, 3168, Australia. alamgeer.muhammad@hudson.org.au. ^[2] Monash University, Wellington Road, Clayton, VIC, 3168, Australia. alamgeer.muhammad@hudson.org.au. ^[3] The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Darlinghurst, NSW, 2010, Australia. ^[4] Monash University, Wellington Road, Clayton, VIC, 3168, Australia. ^[5] Department of Pathology, Monash Medical Centre, 246 Clayton Road, Clayton, VIC, Australia. ^[6] Centre for Cancer Research, Hudson Institute of Medical Research, 27-31 Wright Street, Clayton, VIC, 3168, Australia. ^[7] Department of Medical Oncology, Monash Medical Centre, 246 Clayton Road, Clayton, VIC, 3168, Australia. ^[8] Peninsula and Southeast Oncology, Level 3 Frankston Private, 24-28 Frankston Flinders Road, Frankston, VIC, 3199, Australia. ^[9]

关键词 CD44 Cancer stem cells Hyaluronic acid Small cell lung cancer